You are viewing a preview of this job. Log in or register to view more details about this job.
Applications will be reviewed on a rolling-basis, and this opportunity will remain open until filled.
A research opportunity is currently available in the Office of Pediatric Therapeutics (OPT) underneath the Office of Clinical Policy and Programs (OCPP) at the Food and Drug Administration (FDA) in Silver Spring, Maryland.
Under the guidance of a mentor, the fellow will work on research projects to provide evidence to inform FDA’s public health policy priorities. With collected racial/ethnic demographic information, we intend to develop metrics for assessing whether BPCA/PREA trials include an adequate representation of racial/ethnic subpopulations based on the diseases under study. A literature review will be performed to identify appropriate statistical tests for evaluating proportions of subpopulations within clinical trials and interpretations of “adequacy” of enrollment of racial/ethnic subgroups in clinical trials as it relates to the racial/ethnic demographics of a given disease. Each pediatric clinical trial included in our cohort will be assessed using the established statistical tests and metrics bolstered by a literature review and hiring a post-doctoral ORISE fellow with expertise in statistics. A manuscript for submission to a peer-reviewed journal will follow. Findings that could potentially be used by the Agency to inform new guidance or policy. In addition to the mentor, the fellow will work closely with subject matter experts across the FDA to accomplish project goals. 
 
Potential projects include (but are not limited to) research and analysis of: 
1) Generic drug approvals and market competition;
2) FDA’s foreign inspections of generic drug manufacturers; and
3) The quality of drug marketing applications submitted to the FDA.
While at the FDA, the fellow will have additional learning opportunities such as attending workshops, professional conferences, high-level policy meetings with the director, staff, and FDA senior leadership as well as the opportunity to learn from other work, OCPP/OPT and to explore other parts of FDA.
Anticipated Appointment Start Date: April 3, 2023; start date is flexible
Participants will receive a stipend between $55,000 - $74,000 commensurate with education and experience.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at the FDA facility in Silver Spring, Maryland. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA Ethics Requirements
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA.  For additional requirements, see FDA Ethics for Nonemployee Scientists. FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
  • Non-employee nature of the ORISE appointment;
  • Prohibition on ORISE Fellows performing inherently governmental functions;
  • Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
  • The fact that research materials and laboratory notebooks are the property of the FDA;
  • ORISE fellow’s obligation to protect and not to further disclose or use non-public information.
Qualifications

The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree with completion expected prior to the appointment start date. The degree must have been received within 5 years of the appointment start date.
Preferred skills/ knowledge:
  • Quantitative research (data collection, secondary data analysis, mathematical modeling, etc.) is highly desired.
  • Ability to work independently